Association of serum B-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients

J Invest Dermatol. 2013 Dec;133(12):2786-2788. doi: 10.1038/jid.2013.236. Epub 2013 Jun 3.

Authors

Russell P Hall 3rd¹, Robert D Streilein², Deborah L Hannah², Patrice D McNair², Janet A Fairley³, Arash Ronaghy², Kim D Edhegard², Marc C Levesque²

Affiliations

¹ Department of Dermatology, Duke University School of Medicine, Durham, North Carolina, USA; Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA. Electronic address: Russell.Hall@duke.edu.
² Department of Dermatology, Duke University School of Medicine, Durham, North Carolina, USA; Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
³ Department of Dermatology, University of Iowa School of Medicine, Iowa City, Iowa, USA.

PMID: 23732750
DOI: 10.1038/jid.2013.236

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antibodies, Monoclonal, Murine-Derived / therapeutic use*
Autoantibodies / blood
B-Cell Activating Factor / blood*
Blister / drug therapy
Enzyme-Linked Immunosorbent Assay
Female
Humans
Immunoglobulin G / blood
Immunologic Factors / therapeutic use
Immunologic Memory / immunology*
Male
Middle Aged
Pemphigoid, Bullous / drug therapy*
Precursor Cells, B-Lymphoid / cytology*
Precursor Cells, B-Lymphoid / drug effects
Prednisone / therapeutic use
Rituximab
Treatment Outcome

Substances

Antibodies, Monoclonal, Murine-Derived
Autoantibodies
B-Cell Activating Factor
Immunoglobulin G
Immunologic Factors
TNFSF13B protein, human
Rituximab
Prednisone